Technical Analysis for COYA - Coya Therapeutics, Inc.

Grade Last Price % Change Price Change
F 6.03 -0.66% -0.04
COYA closed down 0.66 percent on Wednesday, November 20, 2024, on 41 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -0.66%
Oversold Stochastic Weakness -0.66%
Wide Bands Range Expansion -0.66%
Down 3 Days in a Row Weakness -0.66%
Down 4 Days in a Row Weakness -0.66%
Down 5 Days in a Row Weakness -0.66%
Oversold Stochastic Weakness -0.66%
Stochastic Reached Oversold Weakness -4.59%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 19 hours ago
Up 3% about 22 hours ago
Up 2% about 22 hours ago
Up 1% about 22 hours ago
Down 1% about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Coya Therapeutics, Inc. Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Immune System Cell Therapy Metabolic Disease Amyotrophic Lateral Sclerosis T Cells Exosome Frontotemporal Dementia Medicinal Products

Is COYA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.6899
52 Week Low 4.75
Average Volume 90,099
200-Day Moving Average 7.53
50-Day Moving Average 7.13
20-Day Moving Average 7.29
10-Day Moving Average 6.76
Average True Range 0.66
RSI (14) 37.11
ADX 22.96
+DI 16.18
-DI 24.17
Chandelier Exit (Long, 3 ATRs) 8.25
Chandelier Exit (Short, 3 ATRs) 7.89
Upper Bollinger Bands 9.51
Lower Bollinger Band 5.06
Percent B (%b) 0.22
BandWidth 61.10
MACD Line -0.35
MACD Signal Line -0.16
MACD Histogram -0.1897
Fundamentals Value
Market Cap 86.86 Million
Num Shares 14.4 Million
EPS -1.24
Price-to-Earnings (P/E) Ratio -4.86
Price-to-Sales 0.00
Price-to-Book 9.72
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.57
Resistance 3 (R3) 6.62 6.49 6.48
Resistance 2 (R2) 6.49 6.35 6.47 6.45
Resistance 1 (R1) 6.26 6.27 6.38 6.21 6.42
Pivot Point 6.13 6.13 6.19 6.11 6.13
Support 1 (S1) 5.90 5.99 6.02 5.85 5.64
Support 2 (S2) 5.77 5.91 5.75 5.61
Support 3 (S3) 5.54 5.77 5.58
Support 4 (S4) 5.49